BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Depomed sinks on dismal drug news]]>http://www.bloggingstocks.com/2009/10/12/depomed-sinks-on-dismal-drug-news/http://www.bloggingstocks.com/2009/10/12/depomed-sinks-on-dismal-drug-news/http://www.bloggingstocks.com/2009/10/12/depomed-sinks-on-dismal-drug-news/#commentsFiled under:

Depomed Inc. (NASDAQ: DEPO) opened Monday on a loss of nearly 50%, as traders panned the company's clinical trial results for Serada. The drug, which is intended to treat hot flashes related to menopause, met only one one of four co-primary goals in late-stage trials after 12 weeks.

Depomed was hoping to prove that Serada could help patients achieve a "statistically significant reduction in the frequency and severity of menopausal hot flashes." However, the company confessed that the placebo effect was unexpectedly high in clinical studies.

Continue reading Depomed sinks on dismal drug news

Depomed sinks on dismal drug news originally appeared on BloggingStocks on Mon, 12 Oct 2009 11:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Carl PelzelDEPODepomedFDAFood and Drug Administrationhot flash druginthenewsSeradatechnical analysisMon, 12 Oct 2009 11:30:00 EST<![CDATA[Market highlights for next week: RIMM to report Q2 earnings]]>http://www.bloggingstocks.com/2007/09/28/market-highlights-for-next-week-rimm-to-report-q2-earnings/http://www.bloggingstocks.com/2007/09/28/market-highlights-for-next-week-rimm-to-report-q2-earnings/http://www.bloggingstocks.com/2007/09/28/market-highlights-for-next-week-rimm-to-report-q2-earnings/#commentsFiled under: , , , , ,

Monday October 1

* Beijing Med-Pharm Corporation (NASDAQ: BJGP) to hold a conference on the acquisition with Sunstone Pharma at 9am.

Tuesday October 2

* Ford Motor Company (NYSE: F) to report monthly sales at 1pm, General Motors Corporation (NYSE: GM) to report monthly sales at 2pm.
* PDUFA date for Biovail Corporation (NYSE: BVF)/Depomed Inc (NASDAQ: DEPO)/King Pharmaceutical Inc's (NYSE: KG) Glumetza for glycemic control in diabetic adults.

Wednesday October 3

* Threshold Pharmaceuticals (NASDAQ: THLD) to discuss Glufosfamide results from Phase III Clinical Trial at 4:30pm.

Thursday October 4

* Constellation Brands (NYSE: STZ) to report Q2 earnings; conference call at 10am.
* Lawson Software (NASDAQ: LWSN) to report Q1 earnings; conference call at 4:30pm.
* Research In Motion (NASDAQ: RIMM) to report Q2 earnings; conference call at 5pm.

Friday October 5

* PDUFA date for Bristol Myers Squibb's (NYSE: BMY) Abilify for the treatment of schizophrenia and manic episodes associated with Bipolar I Disorder.

Market highlights for next week: RIMM to report Q2 earnings originally appeared on BloggingStocks on Fri, 28 Sep 2007 15:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>beijing med-pharmaBeijingMed-pharmabiovailbjgpbmybristol myers squibbBristolMyersSquibbbvfconferenceconstellation brandsConstellationBrandsdepodepomedearningsffordgeneral motorsGeneralMotorsGlufosfamideglumetzagmhighlightinthenewskgking pharmaceuticalKingPharmaceuticallawsonlwsnpdufapreviewresearch in motionResearchInMotionrimmsalesstzthldthresholdFri, 28 Sep 2007 15:30:00 EST<![CDATA[DepoMed: Back to the drawing board on Gabapentin]]>http://www.bloggingstocks.com/2007/07/10/depomed-back-to-the-drawing-board-on-gabapentin/http://www.bloggingstocks.com/2007/07/10/depomed-back-to-the-drawing-board-on-gabapentin/http://www.bloggingstocks.com/2007/07/10/depomed-back-to-the-drawing-board-on-gabapentin/#commentsFiled under: , ,

It's a classic tale: A pharmaceutical company looks for the next big drug only to have that drug fail a late-stage trial. Then shares plummet.

That's exactly what happened to specialty pharmaceutical drug company DepoMed Inc (NASDAQ: DEPO). The company announced earlier today that Gabapentin GR, its experimental drug for nerve pain caused by shingles, failed to meet its primary goal of a late-stage trial. The primary endpoint of the Phase 3 trial was to reduce average daily pain scores, which it did, but only during the initial weeks of the treatment. After that, pain scores in patients treated with the drug were "statistically lower" in comparison with a placebo. The company also said pain relief from the medicine over the course of the study was not "statistically significant," but that the medication proved effective in reducing sleep interference.

That's gotta hurt.

Gabapentin, which is an experimental altered form of Pfizer Inc's (NYSE: PFE) Neurontin, was designed to release through gastric retention, where the drug stays in the stomach and is absorbed. Due to positive Phase 2 clinical trial data, DepoMed was counting on the drug to help it compete against Pfizer's Neurontin and its even newer treatment, Lyrica, as well as other generic drug makers who market Neurontin under the chemical name gabapentin.

Don't look for DepoMed to wave the white flag yet -- the company said it didn't expect the disappointing data to interfere with other efforts to develop Gabapentin GR as a treatment for menopausal hot flashes.

On the announcement, DepoMed shares were down a whopping 60%.

DepoMed: Back to the drawing board on Gabapentin originally appeared on BloggingStocks on Tue, 10 Jul 2007 15:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>clinical trialClinicalTrialDEPODepoMedGabapentinNeurontinPFEPfizerpharmaceuticalPhase 2Phase2shinglesTue, 10 Jul 2007 15:20:00 EST